SEARCH

SEARCH BY CITATION

References

  • 1
    Acute myeloid leukemia in NCCN Clinical Guidelines in Oncology. [Cited 14 Jan 2011.] Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
  • 2
    Fernandez HF, Sun Z, Yao X et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 124959.
  • 3
    Lowenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukema. N Engl J Med 2009; 361: 123548.
  • 4
    Ohtake S, Miyawaki S, Fujita H et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study. Blood 2011; 117: 235865.
  • 5
    Wiernik PH, Banks PLC, Case DC Jr et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 3139.
  • 6
    Feldman EJ, Seiter K, Traganos F et al. Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia. Leuk Lymphoma 2000; 38: 30915.
  • 7
    Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000; 14: 4769.
  • 8
    Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 324454.
  • 9
    Larson RA. Current use and future development of gemtuzumab ozogamicin. Semin Hematol 2001; 38: 2431.
  • 10
    Van DerVelden VH, Te Marvelde JG, Hoogeveen PG et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197204.
  • 11
    Larson RA, Boogaerts M, Estey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 162736.
  • 12
    Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 14906.
  • 13
    Kobayashi Y, Tobinai K, Takeshita A et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calechiamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol 2009; 89: 4609.
  • 14
    Tsimberidou A, Cortes J, Thomas D et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003; 27: 8937.
  • 15
    Alvarado Y, Tsimberidou A, Kantarjian H et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003; 51: 8790.
  • 16
    Chevallier P, Delaunay J, Turlure P et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008; 26: 51927.
  • 17
    Fianchi I, Pagano L, Leoni F et al. Gemtuzumab, cytarabine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol 2008; 19: 12834.
  • 18
    Stone RM, Moser B, Sanford B et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res 2011; 35: 32933.
  • 19
    Kell WJ, Burnett AK, Chopra R et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102: 427783.
  • 20
    Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 232233.
  • 21
    Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 46429.
  • 22
    Dinndorf PA, Andrews RG, Benjamin D et al. Expression of normal myeloid associated antigens by acute leukemia cells. Blood 1986; 67: 104853.
  • 23
    Larson RA, Sievers EL, Stadtmauer EA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 144252.
  • 24
    Piccaluga PP, Martinelli G, Rondoni M et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 2004; 45: 17915.
  • 25
    Tsimberidou AM, Giles FJ, Estey E et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006; 132: 398409.
  • 26
    Burnett AK, Hills RK, Milligan D et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 Trial. J Clin Oncol 2011; 29: 36977.
  • 27
    Petersdorf S, Kopecky K, Stuart RK et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard unduction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114 (abs 790).
  • 28
    Borthakur G, Jappour E, Wang X et al. Effect of front-line therapy with fluradabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). J Clin Oncol 2010; 28: 466s (abs 6552).